 |
|
Imiquimod and Genital Herpes
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Based on very encouraging data from guinea pig studies, several authors
have proposed that 5% imiquimod cream, currently approved for the treatment
of external genital warts, may provide therapeutic benefit in the treatment
of human herpes genitalis.1-2
To our knowledge, there have been 2 reported cases where some benefit was
observed, with no recurrence through 1 and 6 months after therapy, respectively.3-4 In each case, the authors have
called for controlled clinical studies to further examine the question. In
fact, a phase 2, double-blind, placebo-controlled, multicenter study of 124
patients with recurrent genital herpes was performed in September 1998. The
results of this study were presented at the 2001 Interscience Conference on
Antimicrobial Agents and Chemotherapy, and a manuscript has been submitted
for publication.
Without disqualifying the manuscript from consideration, we would like
to advise clinicians that efficacy with the 5% imiquimod cream was observed
to be no different from . . . [Full Text of this Article]
|
